HRS Roundtable: Managing Risk of Premature and Rapid Battery Depletion

Event Recorded:

 

On Demand Product Available through:

05/14/2017 12:01 am

Activity Description:

On October 11, 2016, the U.S. Food and Drug Administration issued a safety communication  alerting health care providers and patients about premature battery depletion in a subset of St. Jude Medical ICD and CRT-D devices.

During this 70 min on-demand webinar, Dr. Gold, Dr. Van Hare, Dr. Slotwiner from the HRS, Dr. Carlson from St Jude Medical, Dr. Selzman and Ms. Paulsen from the U.S. Food and Drug Administration answer the questions submitted during a HRS-hosted Twitter Chat held on October 24, 2016. Among the questions addressed are:

  • Are issues related to lithium clusters unique to the St Jude Medical ICDs and CRT- D manufactured between January 2010 and May 2015? Are you aware of other device models or manufacturers that are affected?
  • How frequently we should interrogate the patients that have existing device?
  • Should all affected patients be on remote monitoring?
  • Were measures taken after May 2015 to mitigate the problem of premature battery depletion?

For more information about this safety alert, please visit the Society’s Safety Alert Resource Center .

Report an adverse event-Medwatch

Location:

Access Activity

Course Directors/Faculty:

Michael R. Gold, MD, PhD, FHRS
President
Heart Rhythm Society

George F. Van Hare, MD, FHRS
President-Elect
Heart Rhythm Society

David J. Slotwiner, MD, FHRS 
Chair, Health Policy Committee
Heart Rhythm Society

Mark D. Carlson, MD, MA
Chief Medical Officer and Vice President Global Clinical Affairs
St Jude Medical

Jessica Paulsen
Branch Chief 
Implantable Electrophysiology Devices Branch
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Kimberly Selzman, MD, FHRS
Medical officer
Implantable Electrophysiology Devices Branch
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Learning Objectives:

  • Explain the details of the safety alert.
  • Understand the implications for patients. 
  • Discuss and answer the questions that were submitted during the twitter chat.